AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma
Shots:
- The EC has granted conditional marketing authorization for Tepkinly as a monotx. for the treatment of adult patients with r/r DLBCL after two or more lines of systemic therapy
- The approval was based on the results from the P-I/II trial (EPCORE NHL-1) evaluating Tepkinly in patients with r/r LBCL incl. subtype DLBCL. The results showed ORR (62%) and a CR rate (39%), m-DoR was 15.5mos. & also demonstrated a manageable safety profile across the LBCL patient cohort incl. the DLBCL patient population
- Tepkinly, an IgG1-bispecific Ab that has been developed using Genmab's DuoBody technology. Epcoritamab was approved in the US under the brand name Epkinly in May 2023 for r/r DLBCL
Ref: PR Newswire | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
